Home » Newsletters » BioWorld Science

BioWorld Science

June 10, 2008

View Archived Issues

Tumor responses associated with PARP inhibition seen in phase I studies with BSI-201

Semafore reports positive interim results from phase I study of PI3K inhibitor SF-1126

Recent patents impart novel compounds for respiratory disorders

Akorn receives FDA approvable letter for Akten ophthalmic gel 3.5%

PAC-113 found effective in the treatment of oral candidiasis in phase IIb dose-ranging trial

New treatment options for neuropsychiatric disorders imparted in recent patents

BTG completes treatments in Varisolve U.S. phase II safety study

Update on clinical studies of Boehringer Ingelheim's Polo-like kinase inhibitor BI-2536

AMANET launches large-scale testing of MSP3-LSP malaria vaccine candidate

FDA grants pediatric exclusivity to UCB's Keppra until January 2009

Prucalopride found safe and effective in patients with chronic constipation

First-in-human results with antisense oligonucleotide LY-2181308 for the treatment of solid tumors

Oncolytics initiates enrollment in phase II trial of Reolysin with paclitaxel and carboplatin

Sirtris' novel SIRT1 activator shows efficacy in mouse models of type 2 diabetes

Akesis completes recruitment and dosing in phase IIa trial of AKP-020 in type 2 diabetes

BioMarin to initiate phase I/II trial in the first quarter of 2009 of new ERT for MPS IVA

Anesiva and TFT enter licensing agreement for NF-kappa B clinical program

Genocea Biosciences and PATH enter collaboration agreement to develop pneumoccocus vaccine

Gentium presents update on DSMB reviews of phase II/III and phase III trials of defibrotide

Inspire achieves primary endpoint in phase III denufosol trial in cystic fibrosis

Vertex reports 52% SVR 12 rate for a 24-week telaprevir-based regimen in HCV

Targanta Therapeutics submits MAA to EMEA for oritavancin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...